SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Oxford BioMedica PLC (OXBDF)

OXBDF RSS Feed
Add OXBDF Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/13/2017 11:25:22 AM - Followers: 4 - Board type: Free - Posts Today: 0

Oxford BioMedica PLC (OXBDF) 
 
Trades In UK as (OXB.L)
  
  
Company website

UK company traded on grey's in US

 

 
Company Address:
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001

 
Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ?wet? age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
 
Management
 
Partnerships 
 
Financial Reports:  http://www.oxfordbiomedica.co.uk/financial-reports/
 
Investor Contacts:  http://www.oxfordbiomedica.co.uk/investor-contacts/
 
 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 
 
 
 
 
 
SureTrader
Interactive Brokers Advertisement
OXBDF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#517   HIV controlled with improved CAR T therapy; human marcusl2 10/13/17 11:25:21 AM
#516   CTL019 has robust activity in DLBCL and triple-refractory marcusl2 10/10/17 12:21:49 PM
#515   Carl June has achieved a complete remission in marcusl2 10/10/17 11:56:52 AM
#514   The start of Kymriah expanding. I think that marcusl2 10/04/17 03:16:38 PM
#513   Broker Forecast - Peel Hunt issues a broker marcusl2 09/20/17 04:27:16 PM
#512   5T4 oncofoetal antigen: an attractive target for immune georgejjl 09/15/17 07:45:47 PM
#511   Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide georgejjl 09/15/17 07:40:04 PM
#510   http://www.bioworld.com/content/novartis-car-ts-kymriah-market-race-next-gen-win marcusl2 09/08/17 05:56:54 AM
#509   https://www.cbsnews.com/news/fda-approves-first-gene-therapy-in-u-s-to-treat-leu marcusl2 09/06/17 04:49:05 PM
#508   http://myfox28columbus.com/good-day-columbus/local-doctor-on-how-car-t-cell-ther marcusl2 09/06/17 04:09:03 PM
#507   The treatment, Kymriah, developed with British Aim-listed biotech marcusl2 09/04/17 01:28:00 PM
#506   http://whyy.org/cms/radiotimes/ marcusl2 09/03/17 03:32:57 PM
#505   https://www.streetwisereports.com/pub/na/small-cap-biotech-benefits-from-first-f marcusl2 09/02/17 11:00:43 AM
#504   A big THANK YOU should go to Emily georgejjl 08/30/17 09:23:26 PM
#503   FDA announces first US gene therapy approval for georgejjl 08/30/17 08:09:15 PM
#502   The FDA approval press release!!! georgejjl 08/30/17 12:28:04 PM
#501   FDA approved the Novartis and Oxford BioMedica treatment georgejjl 08/30/17 12:17:43 PM
#500   But with a market value of a little georgejjl 08/29/17 08:59:16 PM
#499   CAR T 5T4 marcusl2 08/28/17 02:02:26 PM
#498   As previously reported, BTIG upgraded Juno Therapeutics to marcusl2 08/28/17 02:01:50 PM
#497   How do you turn world-leading British science into medicines? marcusl2 08/27/17 05:19:03 AM
#496   http://www.dailymail.co.uk/wires/reuters/article-4816352/Profit-finally-sight-ge marcusl2 08/23/17 11:21:08 AM
#495   http://www.oxfordbiomedica.co.uk/system/files/webcasts-and-audios/interimresults marcusl2 08/17/17 07:33:39 AM
#494   CTL019 and other undisclosed CART products; over $100 marcusl2 08/17/17 04:03:47 AM
#493   HTTPS://www.pennmedicine.org/cancer/navigating-cancer-care/treatment-types/immun marcusl2 08/15/17 05:04:30 AM
#492   Today's Independent: marcusl2 08/15/17 04:04:02 AM
#491   Two CAR T-cell therapy products, in fact, are marcusl2 08/12/17 03:59:06 PM
#490   http://time.com/4895010/cancers-newest-miracle-cure/?utm_source=time.com&utm_med marcusl2 08/12/17 10:49:32 AM
#489   2 million pounds is better than nothing but georgejjl 08/11/17 11:11:28 AM
#488   This will hopefully lead to improved manufacturing; marcusl2 08/11/17 03:39:35 AM
#487   London, UK - 07 August 2017: Oxford BioMedica marcusl2 08/09/17 03:49:53 AM
#486   http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-annou marcusl2 08/07/17 04:33:46 AM
#485   Immune Design's results appear to be very promising ; marcusl2 08/03/17 06:22:55 AM
#484   ADA–SCID This is a partner's product, where Oxford Biomedica georgejjl 08/03/17 12:02:04 AM
#483   A single dose of peripherally infused EGFRvIII-directed CAR georgejjl 08/02/17 11:09:24 PM
#482   georgejjl Saturday, 01/28/17 11:27:04 AM georgejjl 08/02/17 10:53:48 PM
#481   "It's rare to hear regulators refer to the marcusl2 08/02/17 08:00:53 AM
#480   Yes I listened to the meeting live, very marcusl2 08/02/17 08:00:09 AM
#479   Marcus, That was truly amazing. georgejjl 08/01/17 10:12:24 PM
#478   From page 46, CM 17, impressive from OXB marcusl2 08/01/17 12:53:58 PM
#477   Profits with I--- will go to buy some here. JUST 10-11-12 08/01/17 08:09:56 AM
#476   OXB-302 Gene-based immunotherapy targeting a range of cancers georgejjl 07/27/17 07:19:01 PM
#475   Oxford Biomedica has the ability to deliver the marcusl2 07/26/17 04:15:36 PM
#474   BCMA CAR T being done by Bluebird, Penn marcusl2 07/26/17 07:38:45 AM
#473   OXB own 4% plus supply the Lenti marcusl2 07/24/17 04:11:45 PM
#472   https://www.nytimes.com/2017/07/23/health/gene-therapy-cancer.html marcusl2 07/24/17 11:53:07 AM
#471   Too many me thinks JUST 10-11-12 07/18/17 09:52:40 PM
#470   Oxford BioMedica currently has 3.09 billion shares outstanding. georgejjl 07/18/17 09:22:50 PM
#469   Novartis is looking for acquisitions in the $2 georgejjl 07/18/17 08:59:17 PM
#468   Re acquisitions, listen to 4mins. marcusl2 07/18/17 08:45:51 AM
PostSubject